Travere therapeutics to present abstracts at the 17th international symposium on iga nephropathy (iigann 2023)

San diego, sept. 26, 2023 (globe newswire) -- travere therapeutics, inc. (nasdaq: tvtx) today announced that the company and its collaborators will present preliminary findings from the spartan study evaluating the potential effect of filspari® (sparsentan) as a first-line therapy in patients with newly diagnosed iga nephropathy (igan) in a late-breaking trial session at the 17th international symposium on iga nephropathy (iigann2023) in ryogoku, tokyo, september 28-30, 2023.
TVTX Ratings Summary
TVTX Quant Ranking